Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 6/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300117 | 0.90 | USP2 (0.37) | USP2ALDH1A1TP53MAPTPOLB | |
| SCHEMBL2076974 | 0.87 | USP2 (0.35) | USP2ALDH1A1TP53MAPTPOLB | |
| SCHEMBL13007378 | 0.85 | USP2 (0.40) | USP2ALDH1A1TP53MAPTPOLB | |
| SCHEMBL2077751 | 0.84 | USP2 (0.33) | USP2ALDH1A1TP53MAPTLMNA | |
| SCHEMBL2076955 | 0.84 | USP2 (0.33) | USP2ALDH1A1TP53MAPTLMNA | |
| SCHEMBL2078776 | 0.84 | USP2 (0.33) | USP2ALDH1A1TP53MAPTLMNA | |
| SCHEMBL2077748 | 0.84 | USP2 (0.33) | USP2ALDH1A1TP53MAPTLMNA | |
| SCHEMBL2302033 | 0.84 | USP2 (0.33) | USP2ALDH1A1TP53MAPTLMNA | |
| SCHEMBL2078758 | 0.82 | EHMT2 (0.34) | USP2ALDH1A1TP53NQO2 | |
| SCHEMBL2077846 | 0.81 | USP2 (0.36) | USP2ALDH1A1TP53MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | USP2 4560/4885ALDH1A1 813/4885TP53 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.